Loading patent…
AssigneeGenmab B.V.
InventorsJan G.J. van de Winkel, Marcus A. van Dijk, Janine Schuurman, Arnout F. Gerritsen, Ole Baadsgaard, Jorgen Petersen
Estimating the term…
Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
An isolated human monoclonal antibody which specifically binds to human IL-15, comprising at least one CDR sequence selected from the group consisting of:
An isolated human monoclonal antibody which specifically binds to human IL-15, comprising a heavy chain variable region with amino acid sequence SEQ ID NO:
An isolated human monoclonal antibody which specifically binds to human IL-15, comprising a light chain variable region with amino acid sequence SEQ ID NO:
An isolated human monoclonal antibody which specifically binds to human IL-15, which inhibits cis-signalling via the IL-15Rγ-chain by specifically binding to an epitope located on the γ-chain interacting domain of human IL-15, and which inhibits trans-signalling on neighboring cells expressing the γ-chain or the β- and γ-chains as part of IL-15R of another cytokine receptor.
An isolated human monoclonal antibody which specifically binds to human IL-15 and which interferes with IL-15 receptor α-, β- and γ-chain assembly.
An isolated human monoclonal antibody which specifically binds to human IL-15 and which inhibits assembly on neighbouring cells expressing β- and γ-chains as part of the IL-15 receptor or another cytokine receptor.
A method of treating or preventing a disorder that is associated with an overexpression of human IL-15 and/or in which a downregulation or inhibition of human IL-15 induced effects is beneficial, comprising administering to a subject an isolated human monoclonal antibody which specifically binds to human IL-15 in an amount effective to treat or prevent the disorder.
Dependencies are inferred from the claim text.